Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-meso and CART19 in Metastatic Pancreatic Cancer
NCT02465983Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- May 2015
- Primary completion
- Sep 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-meso cells in pancreatic cancer (PC), sponsored by University of Pennsylvania. Primary endpoint: Safety of IV administration of CART-meso-19 with cyclophosphamide at 24 months. Started May 2015; status: terminated.
02
Drugs
CART-meso cells
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02465983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465983.